Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance

Internal Rejuva development will stop as Fractyl expects expense reductions to extend its cash runway into Q2 2027.

Rhea-AI Summary

Fractyl Health (GUTS) is concentrating resources on Revita for post-GLP-1 weight maintenance and plans to reduce its workforce by approximately 45%. Internal development of the Rejuva gene therapy program will stop while strategic alternatives are sought. The changes follow REMAIN-1 pivotal results meeting the prespecified six-month co-primary endpoint for weight regain versus sham (p=0.0023).

Fractyl plans an FDA De Novo marketing application in late Q4 2026 and expects 12-month pivotal data, including the second co-primary endpoint, in Q1 2027. It identifies late 2027 as potential authorization timing and early 2028 for a potential U.S. launch. The company expects existing cash to fund operations into Q2 2027 and quarterly operating cash burn to fall approximately 50% to approximately $8 million by that quarter's end. Workforce reductions are expected to be substantially completed by November 2026.

6 points · 2 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointREMAIN-1 met its six-month co-primary endpoint for weight regain versus sham (p=0.0023).
• Major point. Forward-looking: it has not happened yet and may not happen.Quarterly operating cash burn is expected to fall approximately 50% to approximately $8 million by end of Q2 2027.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Fractyl plans a Revita FDA De Novo marketing application in late Q4 2026.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Fractyl anticipates 12-month pivotal data, including the second co-primary endpoint, in Q1 2027.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Fractyl identifies late 2027 for potential FDA marketing authorization and early 2028 for a potential U.S. launch.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Existing cash is expected to fund operations into Q2 2027, based on planned reductions and expected reprioritization cash costs.

Negative

• Major point. Forward-looking: it has not happened yet and may not happen.Workforce reduction affects approximately 45% of employees, with substantial completion expected by November 2026.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Rejuva internal development will stop while Fractyl seeks strategic alternatives for the gene therapy program.

Argus 15 min delay 4 alerts

-0.85% vs previous close $1.14 last price 15.4x rel. volume Open Argus

Details

Market Reaction – GUTS

+1.1% Peak Tracked

$1.07 – $1.21 Day Range

$15.12M Mkt Cap at Last Price

On Oct 22, the day this news came out, the latest delayed price for GUTS is 0.85% below the previous close. Argus tracked a peak move of +1.1% during the session. Our momentum scanner has recorded 4 alerts for this stock so far that day. The latest delayed price is $1.14. Relative volume is exceptionally heavy at 15.4x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Co-primary endpoint p-value: p=0.0023 Workforce reduction: Approximately 45% Cash runway: Into Q2 2027 +3 more

Co-primary endpoint p-value

p=0.0023

Six-month REMAIN-1 pivotal results versus sham

Workforce reduction

Approximately 45%

Expected to be substantially completed by November 2026

Cash runway

Into Q2 2027

Based on the current operating plan and anticipated expense reductions

Quarterly operating cash burn

Reduced by approximately 50% to approximately $8 million

Expected by the end of Q2 2027

Planned FDA De Novo submission

Late Q4 2026

Revita for post-GLP-1 weight maintenance

Pivotal data readout

Q1 2027

Anticipated 12-month REMAIN-1 data, including the second co-primary endpoint

Historical Context

1 past event · Latest: Oct 16

1 event

1. Oct 16

   Clinical data

   24h Move

   -62.7%

   Six-month REMAIN-1 cohort met its co-primary endpoint; weight regain was 5.1% with Revita versus 8.2% with sham.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

de novo, glp-1, co-primary endpoint

3 terms

de novo regulatory

"planned FDA De Novo submission"

De novo means “starting from scratch” — creating something new rather than buying, copying, or modifying an existing asset. For investors it signals a fresh venture or a first-time regulatory pathway where there is no operating history or precedent, which can mean higher upside if it succeeds but greater risk and uncertainty because outcomes, costs and approvals are less predictable; think of it as backing a new recipe instead of a well-known restaurant.

glp-1 medical

"post-GLP-1 weight maintenance"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

co-primary endpoint medical

"met its prespecified six-month co-primary endpoint"

Two or more outcomes that a clinical trial declares beforehand as its primary measures of success; the trial’s result is judged against each of these measures according to the pre-specified statistical plan. In regulatory and trial practice co-primary endpoints typically require demonstrating the pre-specified effect for each endpoint (or follow the trial’s defined success rule), and they trigger additional statistical controls for multiple comparisons so that the overall error rates remain controlled.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Following positive topline six-month REMAIN-1 pivotal results, Revita advancing toward planned FDA De Novo submission in late Q4 2026 and anticipated 12-month pivotal data readout in Q1 2027

Workforce reduction aligns organization behind Revita's near-term clinical and commercial opportunity

Company discontinuing development of Rejuva candidates and seeking strategic alternatives to maximize the value of its Rejuva gene therapy program

Cash runway extended into Q2 2027; quarterly operating cash burn expected to be reduced by ~50% to approximately $8 million by end of Q2 2027

BURLINGTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it is sharpening its focus and concentrating its financial and operational resources on advancing Revita®, its lead product candidate, toward potential U.S. Food and Drug Administration (FDA) marketing authorization and commercialization in post-GLP-1 weight maintenance.

The decision follows the Company's recent announcement of positive topline six-month results from the REMAIN-1 Pivotal Cohort, which met its prespecified six-month co-primary endpoint with high statistical significance in weight regain compared to sham (p=0.0023). The Company believes these results reinforce Revita's potential to become the first durable procedural therapy for post-GLP-1 weight maintenance, addressing what the Company believes is one of the largest unmet needs in obesity care as millions of patients seek sustainable solutions to maintain weight loss following GLP-1 discontinuation.

To support this sharpened focus, Fractyl will implement a reduction in force affecting approximately 45% of its workforce. These actions are intended to create a streamlined, Revita-focused organization, reduce quarterly cash burn by approximately 50% by the end of Q2 2027 and concentrate resources on realizing Revita's clinical and commercial potential.

Fractyl will also discontinue internal development of its Rejuva gene therapy program and is seeking strategic alternatives to maximize the value of the program.

In conjunction with these organizational changes, Jay Caplan, Co-Founder, President and Chief Product Officer of Fractyl, will retire from his executive roles with the Company, effective October 30, 2026. Mr. Caplan is expected to continue to support the Company as a senior advisor to the leadership team.

"We believe the positive pivotal results from REMAIN-1 represent a defining moment for Fractyl and represent an enormous opportunity for Revita potential to fundamentally change how obesity is treated and offer a durable approach to weight maintenance," said Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl. "A million patients per month in the United States face the challenge of weight regain after discontinuing GLP-1 therapies. Our goal is for Revita to establish an entirely new therapeutic category by aiming to reverse years of diet-induced damage to the gut. We expect the capital we have today to be sufficient to fund our planned De Novo submission and upcoming 12-month pivotal data, and we are excited to focus our attention and align our resources behind our near-term opportunity.

"While these decisions are difficult, particularly those impacting our colleagues, we believe this focused strategy will position Fractyl to operate more efficiently and advance Revita toward its clinical and commercial potential. I also want to personally thank my fellow co-founder, Jay Caplan, for his leadership, partnership and invaluable contributions to Fractyl over the years. Jay has been instrumental in building the Company. We are deeply grateful for his dedication and lasting contributions, as well as those of all our colleagues affected by this transition."

Strategic Actions to Advance Revita, Reduce Cash Burn and Extend Runway

The Company is implementing the following measures to support execution through upcoming potential clinical and regulatory milestones.

• Workforce Reduction: The Company will reduce its workforce by approximately 45%, with the reduction expected to be substantially completed by November 2026.
• Extended Cash Runway: Based on its current operating plan and anticipated expense reductions, including the expected cash costs associated with the reprioritization, the Company expects its existing cash and cash equivalents to fund operations into Q2 2027.
• Reduced Quarterly Cash Burn: As cost reductions take effect and REMAIN-1 Pivotal Cohort expenditures decline, the Company expects operating quarterly cash burn to be reduced by approximately 50%, to approximately $8 million, by end of Q2 2027.
• Rejuva Strategic Alternatives: The Company will discontinue internal development of its Rejuva gene therapy program and seek strategic alternatives to maximize the value of the program. There can be no assurance that the Company's review of strategic alternatives for Rejuva will result in any transaction, and the Company does not intend to disclose further developments unless and until it determines that disclosure is appropriate or required.
  
  

Fractyl Forward: Advancing Revita Toward a New Therapeutic Category in Obesity Care

The Company continues to anticipate the following anticipated milestones:

• Late Q4 2026: Planned FDA De Novo marketing application submission for Revita in post-GLP-1 weight maintenance.
• Q1 2027: Anticipated topline 12-month data from the REMAIN-1 Pivotal Cohort, including the second co-primary endpoint.
• Late 2027: Potential FDA marketing authorization.
• Early 2028: Potential U.S. commercial launch.
  
  

About Revita

The Revita® DMR System is Fractyl’s lead product candidate, designed to remodel the duodenal lining via a single, minimally invasive endoscopic procedure intended to restore healthy nutrient sensing and signaling disrupted by chronic metabolic disease. By targeting duodenal dysfunction, Revita is designed to address an underlying driver of obesity and enable durable weight maintenance following GLP-1 discontinuation. Revita has received FDA Breakthrough Device Designation for weight maintenance in people with obesity who discontinue GLP-1 therapies. Revita is for investigational use only in the United States and is CE marked in the European Union and United Kingdom.

About Fractyl Health

Fractyl is a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes. The Company’s lead product candidate, Revita, is an endoscopic procedural therapy in pivotal development for post-GLP-1 weight maintenance. Fractyl’s goal is to change the course of metabolic disease, advancing treatment from chronic management toward prevention and reversal of disease. Fractyl is headquartered in Burlington, Massachusetts.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact are forward-looking statements. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, without limitation, statements regarding: the potential benefits of the Company's sharpened strategic focus and reprioritization, including the proposed workforce reduction and its anticipated impact on the Company's expenditures and financial runway; the promise and potential impact of the Company's clinical trial data and product candidates, including Revita’s potential for maintaining weight loss after GLP-1 based therapy discontinuation and its potential to be the first procedural therapy for post-GLP-1 weight maintenance; the design, initiation, timing and results of clinical studies or readouts, including readouts from the REMAIN-1 Pivotal Cohort, including 12-month data; the potential launch or commercialization of any of the Company's product candidates or products; the Company's regulatory strategy, including the timing of any potential De Novo marketing application submission and the potential use and benefits of the De Novo pathway (FDA pre-submission feedback is advisory and non-binding, or as to the timing of any such authorization); the potential treatment population or benefits for any of the Company's product candidates or products; the Company's strategic and product development objectives and goals; the Company’s expected quarterly cash burn and cash runway; the Company’s exploration of strategic alternatives for Rejuva and the potential benefits thereof; and the timing of any of the foregoing. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the risks that are discussed more fully in its filings with the Securities and Exchange Commission (the SEC), including the “Risk Factors” section of its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 24, 2026, and other documents it subsequently files with or furnishes to the SEC, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 10, 2026. These forward-looking statements are based on management’s current estimates and expectations. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.

Contact

Brian Luque, Head of Investor Relations and Corporate Development
IR@fractyl.com, 951.206.1200

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does Fractyl Health plan to submit Revita to the FDA and potentially launch it?

Fractyl plans a De Novo marketing application in late Q4 2026 for Revita in post-GLP-1 weight maintenance. The company identifies late 2027 for potential FDA marketing authorization and early 2028 for a potential U.S. commercial launch.

How much does Fractyl Health expect to reduce cash burn?

Fractyl expects quarterly operating cash burn to fall approximately 50% to approximately $8 million by end of Q2 2027. The expectation reflects cost reductions and declining REMAIN-1 Pivotal Cohort expenditures.

What leadership change accompanies Fractyl Health's Revita restructuring?

Co-founder Jay Caplan will retire as President and Chief Product Officer effective October 30, 2026. He is expected to continue supporting the leadership team as a senior advisor.